naa a22 4500 510775942 CHVBK 20180411083230.0 cr unu---uuuuu 180411e20130601xx s 000 0 eng 10.1007/s12975-012-0222-5 doi (NATIONALLICENCE)springer-10.1007/s12975-012-0222-5 Recommendations for Preclinical Research in Hemorrhagic Transformation [Elektronische Daten] [Susan Fagan, Paul Lapchak, David Liebeskind, Tauheed Ishrat, Adviye Ergul] Hemorrhagic transformation (HT) is an important complication of ischemic stroke and is responsible for most of the mortality associated with acute reperfusion therapy. Although many important publications address the preclinical models of ischemic stroke, there are no current recommendations on the conduct of research aimed at understanding the mechanisms and consequences of HT. The purpose of this review is to present the various models used in HT research, the clinical correlates, and the experimental variables known to influence the quantitation of HT in preclinical investigation. Lastly, recommendations for the conduct of preclinical research in HT are provided. Springer Science+Business Media New York, 2012 Hemorrhagic transformation nationallicence Ischemic stroke nationallicence Tissue plasminogen activator nationallicence Animal models nationallicence Hemorrhagic infarction nationallicence Fagan Susan Program in Clinical and Experimental Therapeutics, University of Georgia College of Pharmacy, HM 1212; 1120 15th St, 30912, Augusta, GA, USA aut Lapchak Paul Department of Neurology, Cedars-Sinai Medical Center, Los Angeles, CA, USA aut Liebeskind David UCLA Stroke Center, Los Angeles, CA, USA aut Ishrat Tauheed Program in Clinical and Experimental Therapeutics, University of Georgia College of Pharmacy, HM 1212; 1120 15th St, 30912, Augusta, GA, USA aut Ergul Adviye Program in Clinical and Experimental Therapeutics, University of Georgia College of Pharmacy, HM 1212; 1120 15th St, 30912, Augusta, GA, USA aut Translational Stroke Research Springer-Verlag 4/3(2013-06-01), 322-327 1868-4483 4:3<322 2013 4 12975 https://doi.org/10.1007/s12975-012-0222-5 text/html Onlinezugriff via DOI 1 research-article jats NATIONALLICENCE 856 40 https://doi.org/10.1007/s12975-012-0222-5 text/html Onlinezugriff via DOI NATIONALLICENCE 700 1- Fagan Susan Program in Clinical and Experimental Therapeutics, University of Georgia College of Pharmacy, HM 1212; 1120 15th St, 30912, Augusta, GA, USA aut NATIONALLICENCE 700 1- Lapchak Paul Department of Neurology, Cedars-Sinai Medical Center, Los Angeles, CA, USA aut NATIONALLICENCE 700 1- Liebeskind David UCLA Stroke Center, Los Angeles, CA, USA aut NATIONALLICENCE 700 1- Ishrat Tauheed Program in Clinical and Experimental Therapeutics, University of Georgia College of Pharmacy, HM 1212; 1120 15th St, 30912, Augusta, GA, USA aut NATIONALLICENCE 700 1- Ergul Adviye Program in Clinical and Experimental Therapeutics, University of Georgia College of Pharmacy, HM 1212; 1120 15th St, 30912, Augusta, GA, USA aut NATIONALLICENCE 773 0- Translational Stroke Research Springer-Verlag 4/3(2013-06-01), 322-327 1868-4483 4:3<322 2013 4 12975 Metadata rights reserved Springer special CC-BY-NC licence nationallicence BK010053 XK010053 XK010000 NATIONALLICENCE NATIONALLICENCE NL-springer